SensDx has received positive grant recommendation from Agency of Medical Research for research and mass production implementation of SARS-CoV-2 diagnostics. The research phase will cover optimisation, analytical validation and assessment of clinical effectiveness. The product will be used to detect SARS-CoV-2 virus in a throat or nose swab of patients with COVID-19 symptoms or those infected with SARS-CoV-2 who are asymptomatic.  SensDx solution may be the first screening tool to detect the virus in places of large human flows, such as airports, communication nodes, border controls and other points, strategic for the spread of the epidemic.

The development and introduction to the market of a quick and easy-to-use coronavirus identification test will accelerate the diagnostic process and thereby help to stop the coronavirus epidemic. Rapid diagnostics is a key element in controlling and reducing the epidemic. – emphasizes Dr. Dawid Nidzworski, project manager, CTO at SensDx.

The project is implemented in partnership with the Malopolska Center of Biotechnology of the Jagiellonian University, the Institute of Biotechnology and Molecular Medicine in Gdańsk, the University of Life Sciences in Wrocław, the Regional Specialist Hospital in Wrocław, the Research and Development Center, and the Wroclaw Medical University.,Szybkie-testy-i-zapobieganie-powiklaniom-SARS-CoV-2-z-dofinansowaniem-ABM.html